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Aim: Current guidelines recommend the use of Vitamin K Antagonist (VKA) for up to 3 – 6 
months for treatment of LV thrombus post-acute myocardial infarction (AMI). However, 
based on evidence supporting non-inferiority of Novel Oral Anti-Coagulant’s (NOAC) 
compared to VKA for other indications such as DVT, PE and thrombo-embolic prevention in 
atrial fibrillation, NOACs are being increasingly used off licence for the treatment of LV 
thrombus post AMI. In this study we investigated the safety and effect of NOACs compared 
to VKA on LV thrombus resolution in patients presenting with AMI.  
 
Methods and Results: This was an observational study of 2,328 consecutive patients 
undergoing Coronary Angiography +/- Percutaneous Coronary Intervention (PCI) for AMI 
between May 2015- December 2018, at a UK cardiac centre. Patients’ details were collected 
from the hospital electronic database. The primary end-point was rate of LV thrombus 
resolution with bleeding rates a secondary outcome.   
 
Left ventricular (LV) thrombus was diagnosed in 101 (4.3%) patients. Sixty patients (59.4%) 
were started on VKA and 41 patients (40.6%) on NOAC therapy (rivaroxaban: 58.5%, 
apixaban, 36.5% and edoxaban: 5.0%). Both groups were well matched in terms of baseline 
characteristics including age, previous cardiac history (Previous MI, PCI, CABG), and 
cardiovascular risk factors (Hypertension, Diabetes, Hypercholesterolaemia).  
 
Over the follow up period (median 2.2 years), overall rates of LV thrombus resolution were 
86.1%. There was greater and earlier LV thrombus resolution in the NOAC group compared 
to patients treated with warfarin (82% vs 64.4%, p=0.0018, at 1 year), which persisted after 
adjusting for baseline variables (OR 1.8 95% CI 1.2-2.9). Major bleeding events during the 
f/u period were lower in the NOAC group, compared with VKA group (0% vs 6.7%, p=0.030) 
with no difference in rates of systemic thromboembolism (5% vs 2.4%, p=0.388).  
 
Conclusion: This data suggests improved thrombus resolution in post ACS LV thrombosis 
in patients treated with NOACs compared to vitamin K antagonists. This improvement in 
thrombus resolution was accompanied with a better safety profile for NOAC patients’ vs VKA 

















Left ventricular (LV) thrombus is a recognised complication of acute myocardial infarction 
(AMI) and is associated with a significant thromboembolic risk when left untreated (1, 2). 
Despite advances in interventional cardiology with timely and effective mechanical 
reperfusion, the incidence of LV thrombus in AMI, particularly in anterior AMI patients, 
remains, with reported incidences between 2.7% - 12.3% of all cases (2, 3, 4, 5), with a 
higher incidence of thrombi (between 11.5% and 43%) occurring in those with anterior ST- 
elevation myocardial infarction (STEMI) (6). Due to a reported incidence of 10-40% of 
thromboembolic events occurring in these patients current guidelines (ESC, ACCF/AHA, and 
ACCP) recommend the use of a Vitamin K Antagonist (VKA) for up to 3 – 6 months in 
patients with confirmed LV thrombus post-AMI (7) (8) (9). 
 
Novel oral anticoagulants (NOACs) are highly selective direct factor Xa or thrombin inhibitors 
with oral bioavailability and rapid onset of action (10). They have predictable 
pharmacokinetics across a wide spectrum of patients (age, gender, weight) and have been 
found to be non-inferior or even superior compared to warfarin in the prevention of 
thromboembolic events in patients with non-valvular atrial fibrillation, treatment of thrombo-
embolism (e.g. pulmonary embolism or deep vein thrombosis (DVT)), and prevention of DVT 
(11) (12) (13). NOACs are therefore increasingly used for off licence indications such as the 
treatment of LV thrombus, due to their fixed dosing regimes, low rate of drug interactions, 
and patient convenience with no need for frequent blood tests and possible long-term cost 
savings. However, the assumption of comparability between NOACs and warfarin for other 
indications is potentially problematic for example, higher rates of both ischaemic stroke and 
bleeding were seen when dabigatran was used for thromboprophylaxis of mechanical heart 
valves (14), and a recent observational study suggested superiority for warfarin in all comers 
with LV thrombus (15).     
 
In this study we investigated the contemporary incidence of LV thrombus in AMI patients in 
the primary PCI era, looking at predictors and outcomes specifically assessing the effect of 
NOAC and VKA (warfarin) on LV thrombus resolution. We also assessed resolution time, 














Study design and patient population: This was a single-centre, cohort study of 2,328 
patients conducted at Barts Heart Centre from May 2015 to December 2018. This study was 
designed to assess incidence and outcomes of LV Thrombus but specifically the use of 
NOAC’s as treatment for LV thrombus in patients presenting with AMI undergoing primary 
PCI, providing supportive data for further randomised study. Patients presenting with Non-
ST elevation MI, treated for LV thrombus secondary to alternative aetiologies or already anti-
coagulated for other reasons e.g. AF were not included in the analysis.  
 
Assessment of left ventricular thrombus: In this study, LV thrombus was assessed using 
transthoracic echocardiography, or cardiac magnetic resonance imaging (CMR). All patients 
underwent a screening echocardiographic examination on admission and full study 12–24 h 
after admission. With transthoracic echocardiography, LV thrombus was defined as an 
echodense mass adjacent to an abnormally contracting myocardial segment. LV thrombus 
had to be distinguishable from the underlying myocardium, have a clear thrombus–blood 
interface, and be visible in more than two views. Echocardiography findings were interpreted 
independently by two expert cardiologists, with contrast studies performed as per 
departmental policy in uncertain cases. With gadolinium-enhanced CMR, LV thrombus was 
identified as a LV mass with low-signal intensity surrounded by high-signal intensity 
structures such as intra-cavitary blood or hyper-enhanced infarcted myocardium. Left 
ventricular thrombus was carefully distinguished from microvascular obstruction, which also 
appears as a dark area in the site of infarction, based on the established criteria. Cardiac 
magnetic resonance imaging was performed according to the discretion of the attending 
physicians. 
 
Treatment: Patients with confirmed LV thrombus were anti-coagulated during their in-
hospital stay (range 2-6 days post presentation) with either a Vitamin K Antagonist 
(Warfarin) or NOAC (apixaban, edoxaban or rivaroxaban). Patients not presenting with acute 
or recent AMI were not included in this study. Choice of VKA or NOAC was according to the 
discretion of the attending physicians, with low molecular weight heparin (LMWH) used until 
diagnosis confirmed. Off label use of NOAC was discussed/offered to patients with a 
confirmed diagnosis of LV thrombus. NOAC dose was decided based upon guideline 
recommendations and patient specific factors (i.e renal failure, bleeding risk). Patients with 
LV thrombus were counselled about the guideline-endorsed use of warfarin as the preferred 
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management discussed. This was explained by the physician and a pharmacist. For those 
patients selecting NOAC, the prescription was promptly filled, with the first dose 
administered the same day. Patients initiated on warfarin were treated with concomitant 
LMWH until warfarin was therapeutic. We targeted a therapeutic prothrombin time using an 
international normalised ratio (INR) range of 2.0-3.0 according to ESC guidelines. Triple 
therapy was defined as the combination of dual antiplatelet therapy (DAPT) plus an oral 
anticoagulant.  Aspirin and clopidogrel was the preferred choice of DAPT if deemed 
necessary with anticoagulation, as per ESC guidelines, no potent P2Y12 inhibitors 
(ticagrelor or prasugrel) were used in combination with oral anti-coagulation.   
 
Data Collection: Data were prospectively entered into a database at the time of the 
procedure, with PCI data entered in accordance to the British Cardiovascular Intervention 
Society (BCIS) standards. Data collected included patient characteristics (age, prior 
myocardial infarction (MI), PCI and coronary artery bypass grafting (CABG), hypertension, 
diabetes mellitus, hypercholesterolemia, smoking status, and cardiogenic shock) and 
procedure related data (indications for PCI, target vessel, number of diseased vessels, use 
of intravascular ultrasound (IVUS), optical coherence tomography (OCT), pressure wire, use 
of drug-eluting stent and GPIIb/IIIa inhibitor). 
 
Endpoints: The primary aim was to assess the resolution of LV thrombus measured over 
the study follow-up period (median 2.2 years). All patients underwent imaging (TTE or CMR) 
as planned by the treating physician. Secondary endpoints included bleeding events 
(defined by BARC criteria (16)), thromboembolic events, and death and were recorded 
prospectively. These events were adjudicated by 3 independent physicians [DJ, AB, DW] 
who were not involved in the procedure and were unaware of the patient’s treatment, using 
the patient’s electronic hospital records. Procedural complications recorded included MI, 
emergency CABG, arterial complications, aortic/coronary dissection/perforation, side branch 
occlusion, and arrhythmia. Procedural complications were recorded at the time of the 
procedure and in hospital complications were entered into the database at the time of 
discharge.  
 
Outpatient INR values measured during months 1–6 after the initial prescription of VKA were 
used to classify patients as having ‘good control’ (time in target range (TTR) > 65%) or 
suboptimal control (TTR <65%) (17). We calculated TTR using the method of Rosendaal, 
which incorporates both the frequency of INR measurement and the actual values to 










niversity of London user on 05 August 2020
6 
 
Ethics: Data were collected as part of a national cardiac audit, with the off-license use of 
NOACs discussed with each patient at the time. The local ethics committees advised that 
formal approval was not required.  
 
Statistical Analysis: Baseline patient, procedural, and post-procedural characteristics were 
compared between the 2 groups. Categorical data are summarized using absolute values 
(percentage). Normally distributed, continuous data are presented as mean±SD or, where 
skewed, as median (25th to 75th centile). Normally distributed continuous variables were 
compared using Student t tests, and the Mann-Whitney U test was used to compare non-
normally distributed continuous variables. Categorical data were compared using the 
Pearson chi-squared test. Multivariable logistic regression analysis was used to determine 
independent predictors of LV thrombus formation, using selected covariates. Variables 
associated at univariate analysis with LV thrombus (all with P<0.05) and those judged to be 
of clinical importance from previously published literature were eligible for inclusion into the 
multivariable model. Model discrimination was measured by the C-statistic and calibration by 
the Hosmer-Lemeshow goodness-of-fit test. The Cochran–Armitage test for trend was used 
to test the changes over time. Long-term survival was described by the Kaplan-Meier 
method and comparisons in LV thrombus resolution and survival between groups were 
made using the log-rank statistic. Cox regression analysis was used to estimate hazard 
ratios in the entire population and fully adjusted models, based on covariates (p<0.05) 
associated with the outcome. Variables included in the model including age, gender, 
diabetes mellitus, hypertension, hypercholesterolaemia, previous CABG, previous PCI, 
previous MI, previous cerebrovascular accident (CVA), peripheral vascular disease (PVD), 
multi-vessel disease, Chronic Renal Failure (CRF), left ventricular ejection fraction (LVEF), 
coronary artery treated, and PCI or medical treatment. A two-sided P<0.05 was considered 

















A total of 101 (4.3%) patients with a mean age 59.61 +/- 14.08 years were identified to have 
LV thrombus. Of these acute STEMI patients, the majority (87.1%) presented with anterior 
infarcts (88 patients). In terms of left ventricular ejection fraction (LVEF), 77 (76.2%) had a 
LVEF <40% with a mean LVEF of 34.48% +/-15.0 for the study cohort. 21 patients (20.7%) 
did not undergo early catheter-based revascularization therapy, with the most frequent 
reason late presentation at the hospital (>24 h from AMI onset) in 16 (76.2%) of these 
patients. In the remaining patients, intervention was not performed because of myocardial 
infarction related to previous coronary artery bypass grafting and an undetermined culprit 
lesion.  
 
Patients with LV thrombus tended to be younger, male and present with anterior MI 
(P<0.0001), higher peak troponin T and lower LVEF than patients without LV thrombus 
(Table 1). Of the 101 patients with confirmed LV thrombus, 60 patients (59.4%) were started 
on warfarin and 41 patients (40.6%) were treated with NOAC therapy. The most commonly 
used NOAC was rivaroxaban in 58.5% of cases (15mg in 46.2%, 20mg in 12.3%) followed 
by apixaban in 36.5% (2.5mg bd in 17%, 5mg bd in 19.5%) and edoxaban in the remaining 
5% (30mg in 2.5% and 60mg in 2.5%) of cases.  
 
For diagnosis of LV thrombus all patients underwent screening echocardiograms post PCI 
(+/- Contrast in 22.8%) to identify thrombus. 70.3%of these patients also underwent 
additional CMR pre-discharge with no difference seen in CMR utilisation for diagnosis 
between groups (66.7% VKA, 73.2% NOAC, P=0.518)  
 
Baseline patient, presentation and procedural characteristics (Table 2)  
Both groups were well matched in terms of baseline characteristics including age, previous 
cardiovascular history, and cardiovascular risk factors. The degree of LV impairment (LVEF 
< 40%) was similar in both groups, with similar usage of DES. Similar rates of patients not 
undergoing revascularisation and use of DAPT at discharge were seen between the groups. 
Among all patients with LV thrombus, 70 patients (69.3%) were on triple therapy at 
discharge with a median duration of 3 months (IQR 1-3 months). No difference in the rate of 
concomitant DAPT was seen between groups (70.0% VKA vs 68.3% NOAC) or duration (1 
month: 19.0% VKA, 21.4% NOAC, 3 months: 81% VKA, 78.6% NOAC).  
 









niversity of London user on 05 August 2020
8 
 
Sixty-five (64.3%) of the 101 patients underwent a follow-up CMR with 36 (35.7%) 
undergoing TTE surveillance. No difference in the utilisation rates of CMR was seen 
between the two groups (61.7% CMR in VKA, 68.3% NOAC (p=0.532)). Overall rates of LV 
thrombus resolution were 86.1% over the follow-up up period with an average median time 
to thrombus resolution of 211 days. Median time to 1st imaging was 151 days (IQR 63-352) 
for the NOAC group and 175 days (98-340) for the VKA group (P=0.414). 29 patients 
(70.7%) in the NOAC group and 29 patients (48.3%) in the VKA had resolution of thrombus 
noted on their first follow-up imaging (p=0.04). Over the remaining time period there was a 
consistent significant improvement in LV thrombus resolution with NOAC use compared to 
VKA use (p=0.002). Comparing treatment outcome at different time points (figure 1) 
throughout the follow up period demonstrated quicker thrombus resolution in the NOAC 
treated group compared to VKA group (1-year 82% vs 64.4%, p=0.0018).  This difference in 
resolution rate persisted after adjusting for baseline variables (OR 1.8 95% CI 1.2-2.9). 
Thrombus resolution rates were 88%, 93%, and 100% for rivaroxaban, apixaban, and 
edoxaban, respectively. Post discontinuation of OAC, 38 patients (43.6%) underwent further 
surveillance imaging (81.5% TTE) which showed no recurrence of thrombus.   
 
Oral anticoagulation was discontinued in 76 (75.2%) of 101 patients during the follow-up 
period. The most common reasons for anticoagulation discontinuation were disappearance 
of LV thrombus in 71 (93.4%) patients, a bleeding event in 4 (5.3%) patients, and patient 
preference for one patient. Overall median duration of treatment with NOACs was 
significantly shorter (5.1 months vs 8.7months) compared to warfarin therapy (p=0.02), due 
to earlier thrombus resolution.  
 
Time in Range 
Overall of the patients taking VKA’s, 32 patients (53.3%) were classified as having good 
control with the remaining 28 (46.7%) suboptimal. Of those with suboptimal control, 22 
(75%) were below the therapeutic range with 6 (25%) above the therapeutic range.  A trend 
to greater thrombus resolution was seen in patients who had good compared to sub-optimal 
control over the follow-up period (p=0.0822).   
 
Thromboembolism 
Overall information on secondary endpoints of thromboembolism and bleeding were 
available in all patients with none lost to follow up (Median length of f/u 2.2years).  Rates of 
systemic thromboembolism were low in the study cohort (4.0%) with all events involving the 
brain (n=4, 100%). No difference in event rates were seen between the 2 treatment groups 
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group occurred in individuals who had sub-optimal TTR (<65%), with no events occurring in 
those with good control. No events occurred in patients on triple therapy, with events 
occurring in patients on single (n=1, VKA group 8 months) or no anti-platelet agents (n=3) 
(VKA group, events at 9 and 12 months, NOAC group event at 13 months).   
 
Bleeding  
Similar bleeding risks as assessed by the HAS-BLED score were documented in the 2 
groups with no difference seen between the 2 groups. The incidence of major bleeding 
events as assessed by (BARC >2) in the VKA group was 6.7% compared to the NOAC 
group (0%, p=0.03). These events included gastrointestinal bleeding (3.3%), sub arachnoid 
haemorrhage (1.7%), and epistaxis requiring hospital admission (1.7%). These bleeding 
events occurred on triple therapy in 2 patients and dual therapy in the other 2. No major 
bleeding events were seen with adjunctive anti-platelet therapy in the NOAC group.  Minor 

















The major findings of this study are: (i) the prevalence of LV thrombus was 4.3% in patients 
presenting with acute myocardial infarction in our centre; (ii) overall rates of thrombus 
resolution were 86.1% during the follow up period (iii) there were greater and earlier 
resolution of LV thrombus in the NOAC group compared to patients treated with warfarin 
(81% vs 63%, p=0.0018, at 1 year), which persisted after adjusting for baseline variables 
(OR 1.8 95% CI 1.2-2.9); (iv) major bleeding such as as intracranial bleed, major GI bleed 
and bleed requiring hospital admission were lower in NOAC group, compared with VKA 
group (0% vs 6.7%, p= 0.030) with no difference in rates of systemic thromboembolism 
(p=0.388). 
 
Previous studies have reported the incidence of LV thrombus in patients presenting with AMI 
ranging from 2.7% to 12.3% (19) (20) (21) (2, 4, 5), with a higher incidence of thrombi 
(between 11.5% and 43%) occurring in those with anterior STEMI (6) (22) The contemporary 
incidence of LV thrombus (4.3%) in this study is likely to represent the improvement that has 
been seen in re-perfusion therapy with primary PCI and the use of echocardiography as the 
first line cardiac imaging for primary screening of LV thrombus. Using delayed enhancement 
CMR as the reference, echocardiography is shown to have a sensitivity of 33%, specificity of 
91% and positive and negative predictive values of 29% and 93% respectively (23) (24). 
CMR was used to confirm equivocal cases and monitor resolution rather than being the 
screening tool, which may have led to higher rates of LV thrombus detection.  
 
Current guidelines recommend the use of VKA in the treatment of LV thrombus. There are 
clinical limitations in its use; in particular multiple food and drug interaction, slow onset of 
actions, narrow therapeutic range, haemorrhagic complications, the need for frequent 
monitoring and therefore long-term cost implications. These limitations can be overcome by 
the use of NOACs as they have shown to have predictable efficacy, fixed dosing strategy, 
favourable safety profile, fewer drug interactions, and more rapid onset of effect, consistent 
anticoagulation and without the need for frequent blood monitoring. In addition, a potential 
benefit of NOACs over VKA is the statistically significant reduction in the risk of intracranial 
haemorrhage (ICH) (~50% RRR) (25), although less evidence is available to support this 
reduction with the addition of single or dual anti-platelet therapy. Consistent ICH rates of 1-
1.3% are seen with VKA and DAPT (triple therapy) in registries (26), or large RCTs (27–29),  
which is similar to the rates seen in our study. Despite.the hazard ratio of ICH being reduced 
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AF) from 1.61 (1.23-2.10) in comparison to using VKA monotherapy vs a hazard ratio of 
DOAC triple therapy of 0.9 (0.34-2.40) (30), similar significant results have not yet been 
replicated in randomised studies nor in this analysis despite promising trends (28, 29). 
Noting the high incidence of triple therapy in our population, recommendations of aspirin and 
clopidogrel in combination of a NOAC could suggest a reduction in major bleeding overall 
and in particular the risk of ICH, although further study is still needed.  
 
Previous case studies have demonstrated NOACs to be effective in patients with LV 
thrombus and AMI, with case studies showing efficacy of rivaroxaban (31),  apixaban (32), 
dabigatran (110mg twice daily) (33) and edoxaban (34), with a review of all case series 
suggesting safety of the drugs (35). However, despite these positive case studies a recent 
observational study of 514 patients with LV thrombi (all indications) showed a significant 
association between NOAC use and systemic embolization when compared to warfarin use 
(15). Importantly though this detrimental signal was lost when just patients with an ischaemic 
aetiology of LV thrombus i.e. AMI or cardiomyopathy were looked at suggesting possible 
equivalence or non-inferiority in this group. Although there are no current randomised 
controlled trials or guideline recommendations considering the use of NOACs for treatment 
of LV thrombus in AMI setting, findings of our study are encouraging and support its off-label 
use for such purposes. As data on their use in the treatment of LV thrombus are limited to 
small number of case studies and observational studies, randomised controlled trials are 




This study is an observational, prospective analysis of a large cohort of patients, however 
the number of patients treated for LV thrombus and specifically with NOACs is small. 
However, this is the largest contemporary series assessing LV thrombus post STEMI and 
includes the largest number of patients treated with NOACs for this purpose.  
 
The key limitations relate to the small sample size and the non-randomised nature of this 
study. This observational design means that despite efforts to correct for confounding 
variables, there are likely to be residual confounders that we have been unable to correct for. 
Additionally, be design we have used convenience sampling where it could be argued that 
there may have been risks of selection bias, however all attempts possible to avoid this have 
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standing however in no cases was this felt to be the case at the time. Furthermore, we 
cannot extrapolate these findings to all NOACs because in out institution we did not use 
dabigatran for the treatment of LV thrombus and because of its different mechanism of 




This hypothesis generating study suggests improved thrombus resolution in post ACS LV 
thrombosis in patients treated with NOACs compared to VKA. This improvement in thrombus 
resolution was accompanied with a better safety profile for the NOAC patients’ versus VKA 
treated patients.  This supports the need for randomised controlled trials to confirm this 













Table 1: Clinical Characteristics in AMI patients comparing those with and 
without LV Thrombus 
 
 
No LV Thrombus 
(n= 2,227) 
LV Thrombus 
(n = 101) 
P value 
Age (mean+/-SD)  64.88±15.1 59.61 ±14.1 <0.001 
Male, n (%) 1700 (76.3) 86 (85.1) 0.307 
  
Past Medical History  
Current Smoker, n (%) 675 (30.3) 28 (27.7) 0.656 
Hypercholesterolaemia, n (%) 802 (36.0) 38 (37.6) 0.823 
Hypertension, n (%)  1033 (46.4) 45 (44.6) 0.796 
Diabetes mellitus, n (%) 416 (18.7) 17 (16.8) 0.738 
Prior Myocardial infarction, n (%)  376 (16.9) 16 (15.8) 0.894 
Previous PCI, n (%) 285 (12.8) 11 (10.9) 0.682 
Peripheral Vascular Disease, n (%) 68 (3.1) 2 (1.9) 0.749 
Renal Failure, n (%) 192 (8.6) 9 (8.9) 0.936 
  
LVEF (mean +/-SD) 46.1 ± 14.0 34.5 ±9.6 <0.001 
Anterior infarction, n (%) 817 (36.7) 88 (87.8) <0.001 
Peak Troponin T (hs, ng/L) (median, IQR) 3100 (2400-7300) 7200 (2200-9000) <0.001 
Cardiogenic Shock, n (%) 180 (8.1) 8 (7.9) 0.898 
    
Medical Treatment, n (%)  98 (4.4) 21 (20.7) <0.001 
Percutaneous Coronary Intervention, n (%)  2129 (95.6) 80 (79.3) 0.800 















Table 2: Clinical Characteristics in Patients with Left Ventricular Thrombus who 






(n = 41) 
P 
value 
Age (mean+/-SD) 60.81±14.3 58.73 ±14.2  0.201 
Male, n (%) 51 (85) 33 (80.4) 0.302 
  
Past Medical History  
Current Smoker, n (%) 20 (33.3) 8 (21) 0.175 
Hypercholesterolaemia, n (%) 19 (31.7) 19 (50) 0.150 
Hypertension, n (%) 22 (36.4) 23 (60.5) 0.068 
Diabetes mellitus, n (%) 10 (16.7) 7 (18.4) 0.999 
 Prior Myocardial infarction, n (%) 22 (36.7) 21 (55.3) 0.140 
Peripheral Vascular Disease, n (%) 1 (1.7) 1 (2.6) 0.999 
Renal Failure, n (%) 5 (8.3) 5 (12.1) 0.522 
Mean Baseline eGFR (+/-SD_ 66.11 ± 18.8 68.24 ± 15.8 0.230 
Prior History of Malignancy 7 (11.6%) 6 (14.6%) 0.765 
  
LVEF (mean +/-SD) 35.4 ± 9.0 33.5 ±10.0 0.854 
Anterior infarction, n (%) 52 (86.7) 36 (87.8) 0.710 
HAS-BLED Score (mean ± SD) 2.6 ± 1.0 2.7 ± 1.0 0.746 
    
Medical Treatment, n (%) 12 (20.0) 9 (21.9) 0.850 
Percutaneous Coronary Intervention, n (%)  48 (80.0) 32 (78.1) 0.800 
Drug-Eluting Stent Use, n (%) 46 (95.8) 31 (96.7) 0.833 
  
Medical therapy at D/C 0.688 
Triple therapy 42 (70.0) 28 (68.3)  
Anticoagulation + Single antiplatelet  13 (21.7) 10 (24.4)  














Table 3: Clinical Characteristics in Patients with Left Ventricular Thrombus who 






(n = 41) 
P value 
Systemic thromboembolic Events  
    
Cerebral (CVA) 3 (5%) 1 (2.4) 0.388 
  
Bleeding (BARC type, n (%)  
BARC 1 15 (25.0) 6 (14.6) 0.318 
BARC 2  4 (6.7) 0 (0) 0.147 
BARC 3a 1 (1.7) 0 (0) 1.000 
BARC 3b 1 (1.7) 0 (0) 1.000 
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Figure 1. Bar chart comparing rates of thrombus resolution between NOAC and 
Vitamin K antagonists. A significant unadjusted difference in rates of resolution was 
observed between patients on NOACs compared with patients who on vitamin K antagonists 
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